Sarepta Sells Arrowhead Stake to Extend Cash Runway and Fund Milestones
Sarepta Therapeutics sold its entire stake in Arrowhead Pharmaceuticals to improve its cash position amid challenges with its gene therapy product, Elevidys, leading to a significant drop in Arrowhead's stock price and raising concerns about Sarepta's financial outlook and future drug development prospects.